← All indications
Severe Dengue
A virulent form of dengue characterized by THROMBOCYTOPENIA and an increase in vascular permeability (grades I and II) and distinguished by a positive pain test (e.g., TOURNIQUET PAIN TEST). When accompanied by SHOCK (grades III and IV), it is called dengue shock syndrome.
Drugs by status
Phase 3 trials (14)
- montelukast
- ringer's lactate
- albumin (Human)
- pneumococcal 13-valent conjugate vaccine
- ribavirin
- hepatitis a vaccine, inactivated
- live, attenuated, dengue serotype 1, 2, 3, 4 virus
- live tetravalent chimeric dengue vaccine
- measles, mumps, and rubella vaccine
- hpv 16/18 vaccine
- haemophilus influenzae type b conjugate vaccine
- lactic acid
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- Bivalent group A and C meningococcal vaccine
Phase 2 trials (12)
Phase 1 trials (2)
Other trials (2)
Organizations
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (8)
Organization Involved with Phase 1 Indications (3)